Mark Purcell
Stock Analyst at Morgan Stanley
(1.15)
# 3,678
Out of 5,182 analysts
7
Total ratings
50%
Success rate
-5.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Maintains: Overweight | $143 → $170 | $144.47 | +17.67% | 2 | Mar 26, 2026 | |
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $45.91 | +26.33% | 2 | Sep 8, 2025 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $54.34 | -19.03% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $187.60 | -54.69% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $41.20 | +191.26% | 1 | Jan 23, 2024 |
Novartis AG
Mar 26, 2026
Maintains: Overweight
Price Target: $143 → $170
Current: $144.47
Upside: +17.67%
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $45.91
Upside: +26.33%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $54.34
Upside: -19.03%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $187.60
Upside: -54.69%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $41.20
Upside: +191.26%